Latest:
TechSectors: Connectivity: Improving Physician-Patient Communication
More than ever before, healthcare professionals are strapped for time.
- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2025 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Authors
Fred Saad, CQ, MD, FRCS, FCAHS
Fred Saad, CQ, MD, FRCS, FCAHS, is the director of Prostate Cancer Research at Montreal Cancer Institute, Centre Hospitalier de l’Université de Montréal. He is also a full professor in the Department of Surgery at Université de Montréal and a uro-oncologist in the Urology Department at the University of Montreal Health Center.
Latest:
Dr Saad on the Importance of Timing When Incorporating Radium-223 Into Prostate Cancer Treatment
Fred Saad, MD, discusses the importance of timing when incorporating radium-223 into prostate cancer treatment.
Fred Saad, MD, FRCS
Latest:
The ARANOTE Phase 3 Trial of Darolutamide Plus Androgen-Deprivation Therapy in Patients With Metastatic Hormone-Sensitive Prostate Cancer: Efficacy and Safety by Disease Volume
Dr. Fred Saad presents a post-hoc analysis of the Phase 3 ARANOTE trial, demonstrating that darolutamide plus androgen-deprivation therapy significantly improves radiographic progression-free survival and delays metastatic castration-resistant prostate cancer in patients with metastatic hormone-sensitive prostate cancer, with consistent efficacy across disease volume subgroups and a favorable safety profile.
Frederic Triebel, MD, PhD
Latest:
Dr. Triebel on the Rationale for a Novel Immunotherapy Combination in Melanoma
Frederic Triebel, MD, PhD, chief scientific officer and chief medical director, Immutep Ltd, discusses the rationale for a novel immunotherapy combination in patients with unresectable or metastatic melanoma.
Frederic Zenhausern, PhD, MBA
Latest:
Platform Technology Development for Biologically Targeted Dosimetry and Radiotherapy
The ability to obtain high-quality radiobiological information about the interactions between tumor and healthy tissue, when using ionizing radiations, would contribute to the development of more effective
and personalized radiotherapy treatments.
Frederick Locke, MD
Latest:
Future Perspectives for the Treatment of Relapsed/Refractory DLBCL
A reflection on key accomplishments in DLBCL treatment, highlighting pivotal developments that have shaped clinical practice, followed by a look ahead to 2025, focusing on areas poised for significant progress and personal goals for the coming year
Funda Meric-Bernstam, MD
Funda Meric-Bernstam, MD, is chair of the Department of Investigational Cancer Therapeutics–the Phase I Program, medical director of the Institute for Personalized Cancer Therapy (IPCT), and the Nellie B. Connally Chair in Breast Cancer, at the University of Texas MD Anderson Cancer Center.
Latest:
Dr Meric-Bernstam on the Efficacy and Safety of Dato-DXd in Metastatic Urothelial Cancer
G. Thomas Budd, MD
Latest:
Dr. Budd on Prior Trastuzumab and Paclitaxel Regimens
G. Thomas Budd, MD, Medical Oncologist, Taussig Cancer Center at Cleveland Clinic, Professor, Hematology & Medical Oncology, Case Western Reserve University, discusses prior treatment with trastuzumab and the effect on two regimens of paclitaxel.
Gabriel Mannis, MD
Latest:
Dr. Mannis on Targeted Agents in the Treatment of Patients With AML
Gabriel Mannis, MD, assistant professor, University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, discusses the FDA approval and potential approval of 2 new agents that will provide a more nuanced treatment approach for patients with acute myeloid leukemia (AML).